Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the 10 Most Undervalued Value Stocks to Buy Now.

Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating

A closeup shot of a laboratory technician handling a medical device used for fertility treatments.

Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on August 6, 2025, maintaining a ‘Neutral’ rating. The analyst attributed the target revision to strong results. At the same time, Citi advised caution regarding continued policy uncertainties.

Pfizer Inc. (NYSE:PFE) reported 10% revenue growth, taking total revenue to $14.7 billion. The top-line growth was driven by strong sales of the Vyndaqel product family, Comirnaty, Paxlovid, Padcev, Eliquis, and other products. At the quarter-end, the company also reiterated its 2025 revenue guidance of $61.0-$64.0 billion, while raising its adjusted diluted EPS outlook by $0.10 at the midpoint to $2.90-$3.10. This guidance raise was made despite challenges caused by the Inflation Reduction Act’s Medicare Part D redesign.

Pfizer Inc. (NYSE:PFE) discovers, develops, and markets biopharmaceutical products globally. It is included in our list of the most undervalued value stocks to buy.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.